NewLink Genetics Corp (NASDAQ:NLNK) saw a large decrease in short interest in the month of November. As of November 29th, there was short interest totalling 1,620,000 shares, a decrease of 13.8% from the November 14th total of 1,880,000 shares. Currently, 5.6% of the company’s shares are sold short. Based on an average daily volume of 295,400 shares, the days-to-cover ratio is presently 5.5 days.
Several hedge funds have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC increased its holdings in shares of NewLink Genetics by 70.9% during the 3rd quarter. Tower Research Capital LLC TRC now owns 34,712 shares of the biotechnology company’s stock worth $55,000 after buying an additional 14,395 shares during the last quarter. Wedbush Securities Inc. acquired a new stake in shares of NewLink Genetics during the 3rd quarter worth $41,000. Jane Street Group LLC acquired a new stake in shares of NewLink Genetics during the 2nd quarter worth $178,000. Paloma Partners Management Co acquired a new stake in shares of NewLink Genetics during the 2nd quarter worth $191,000. Finally, Worth Venture Partners LLC increased its holdings in shares of NewLink Genetics by 32.9% during the 2nd quarter. Worth Venture Partners LLC now owns 326,507 shares of the biotechnology company’s stock worth $483,000 after buying an additional 80,858 shares during the last quarter. Institutional investors and hedge funds own 27.46% of the company’s stock.
Shares of NLNK stock traded up $0.02 on Friday, reaching $1.63. 219,154 shares of the stock were exchanged, compared to its average volume of 186,076. The stock has a market cap of $60.45 million, a P/E ratio of -1.13 and a beta of 0.99. The firm has a 50 day moving average of $1.56 and a two-hundred day moving average of $1.56. NewLink Genetics has a 1-year low of $1.13 and a 1-year high of $2.27.
Separately, Zacks Investment Research lowered NewLink Genetics from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd.
NewLink Genetics Company Profile
NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing Indoximod, an indoleamine-2, 3-dioxygenase (IDO) pathway inhibitor that is in clinical development in combination with other cancer therapeutics for patients with diffuse intrinsic pontine glioma, pediatric brain tumors, acute myeloid leukemia, and melanoma.
Featured Article: How is a Moving Average Calculated?
Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.